tirzepatide patent expiration date us Top drug expirations in next 5 years Semaglutide & Tirzepatide Patent Considerations

Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness

Ro has helped over 80,000 members lose weight with GLP-1s

The duration of Mounjaro treatment for weight loss depends on the patients weight loss goals and how well they respond to the medication

Semaglutide may be preferred when a more extensive cardiovascular outcome portfolio is desired (e.g., SELECT and other CVOT data in ASCVD and obesity), or when natriuretic peptide reduction is particularly relevant [40, 50, 53, 57]

Glycine and B12 may help reduce fatigue and enhance tolerability

The peptide cost calculator on our site lets you input vial price and configuration to determine your exact cost per dose and cost per month at any titration stage